(NASDAQ:OCS) ZUG, Switzerland, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (âOculisâ), a global biopharmaceutical company focused on innovations for ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced, in collaboration with EURETINA, the winner of the Ramin Tadayoni Award 2025.